Roberto Minutolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/328297/publications.pdf

Version: 2024-02-01

151 papers

6,089 citations

45 h-index 72 g-index

160 all docs

160 does citations

160 times ranked 5451 citing authors

#	Article	IF	CITATIONS
1	Prognostic Role of Ambulatory Blood Pressure Measurement in Patients With Nondialysis Chronic Kidney Disease. Archives of Internal Medicine, 2011, 171, 1090-8.	3.8	256
2	Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. American Journal of Kidney Diseases, 2001, 38, 18-25.	1.9	242
3	Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. American Journal of Kidney Diseases, 1999, 33, 851-856.	1.9	228
4	A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney International, 2017, 91, 1224-1235.	5.2	210
5	Prevalence and Prognostic Role of Resistant Hypertension in Chronic Kidney Disease Patients. Journal of the American College of Cardiology, 2013, 61, 2461-2467.	2.8	139
6	Salt Intake and Renal Outcome in Patients with Progressive Renal Disease. Mineral and Electrolyte Metabolism, 1998, 24, 296-301.	1.1	135
7	Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes. American Journal of Kidney Diseases, 2014, 64, 16-24.	1.9	132
8	Changing the Timing of Antihypertensive Therapy to Reduce Nocturnal Blood Pressure in CKD: An 8-Week Uncontrolled Trial. American Journal of Kidney Diseases, 2007, 50, 908-917.	1.9	120
9	Global approach to cardiovascular risk in chronic kidney disease: Reality and opportunities for intervention. Kidney International, 2006, 69, 538-545.	5.2	112
10	Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney International, 2007, 71, 245-251.	5.2	112
11	Early Changes in Bioelectrical Estimates of Body Composition in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 1481-1487.	6.1	109
12	Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 271-279.	4.5	107
13	Dietary Salt Restriction in Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials. Nutrients, 2018, 10, 732.	4.1	107
14	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 2021, 99, 1280-1295.	5.2	103
15	Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. American Journal of Kidney Diseases, 2002, 39, 266-273.	1.9	102
16	Detection and Awareness of Moderate to Advanced CKD by Primary Care Practitioners: A Cross-sectional Study From Italy. American Journal of Kidney Diseases, 2008, 52, 444-453.	1.9	98
17	Assessment of Achieved Clinic and Ambulatory Blood Pressure Recordings and Outcomes During Treatment in Hypertensive Patients With CKD: A Multicenter Prospective Cohort Study. American Journal of Kidney Diseases, 2014, 64, 744-752.	1.9	96
18	Nutritional treatment of advanced CKD: twenty consensus statements. Journal of Nephrology, 2018, 31, 457-473.	2.0	95

#	Article	IF	CITATIONS
19	Postdialytic Rebound of Serum Phosphorus. Journal of the American Society of Nephrology: JASN, 2002, 13, 1046-1054.	6.1	94
20	Achievement of target blood pressure levels in chronic kidney disease: a salty question?. American Journal of Kidney Diseases, 2004, 43, 782-795.	1.9	91
21	Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. Cardiovascular Diabetology, 2021, 20, 145.	6.8	91
22	Prognosis of CKD Patients Receiving Outpatient Nephrology Care in Italy. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2421-2428.	4.5	88
23	Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients. Kidney International, 2000, 58, 417-424.	5.2	84
24	Association of Body Mass Index with Clinical Outcomes in Non-Dialysis-Dependent Chronic Kidney Disease: A Systematic Review and Meta-Analysis. CardioRenal Medicine, 2016, 6, 37-49.	1.9	83
25	Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure. Kidney International, 2003, 64, 1822-1828.	5.2	82
26	Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008–12 National Health Examination Survey. Nephrology Dialysis Transplantation, 2015, 30, 806-814.	0.7	82
27	Hypertension and Prehypertension and Prediction of Development of Decreased Estimated GFR in the General Population: A Meta-analysis of Cohort Studies. American Journal of Kidney Diseases, 2016, 67, 89-97.	1.9	81
28	Incremental dialysis in ESRD: systematic review and meta-analysis. Journal of Nephrology, 2019, 32, 823-836.	2.0	77
29	Antiproteinuric Response to Dual Blockade of the Renin-Angiotensin System in Primary Glomerulonephritis: Meta-analysis and Metaregression. American Journal of Kidney Diseases, 2008, 52, 475-485.	1.9	76
30	Low-protein diets for chronic kidney disease patients: the Italian experience. BMC Nephrology, 2016, 17, 77.	1.8	76
31	The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care. Kidney International, 2012, 82, 482-488.	5.2	75
32	Cardiorenal prognosis by residual proteinuria level in diabetic chronic kidney disease: pooled analysis of four cohort studies. Nephrology Dialysis Transplantation, 2018, 33, 1942-1949.	0.7	74
33	Cardiovascular Risk Factors and Disease Management in Type 2 Diabetic Patients With Diabetic Nephropathy. Diabetes Care, 2006, 29, 498-503.	8.6	65
34	Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrology Dialysis Transplantation, 2013, 28, 3035-3045.	0.7	65
35	Long-term visit-to-visit office blood pressure variability increases the risk of adverse cardiovascular outcomes in patients with chronic kidney disease. Kidney International, 2013, 84, 381-389.	5.2	65
36	Risk of ESRD and Death in Patients with CKD Not Referred to a Nephrologist. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1586-1593.	4.5	65

3

#	Article	IF	Citations
37	Effect of a Low- Versus Moderate-Protein Diet on Progression of CKD: Follow-up of a Randomized Controlled Trial. American Journal of Kidney Diseases, 2009, 54, 1052-1061.	1.9	64
38	Effects of Water Hardness on Urinary Risk Factors for Kidney Stones in Patients with Idiopathic Nephrolithiasis. Nephron, 1999, 81, 66-70.	1.8	62
39	High cardiovascular risk in patients with Type 2 diabetic nephropathy: the predictive role of albuminuria and glomerular filtration rate. The NID-2 Prospective Cohort Study. Nephrology Dialysis Transplantation, 2012, 27, 2269-2274.	0.7	60
40	Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings. Journal of Hypertension, 2006, 24, 1655-1661.	0.5	59
41	Effect of Increased Convection Volume by Mid-Dilution Hemodiafiltration on the Subclinical Chronic Inflammation in Maintenance Hemodialysis Patients. Blood Purification, 2019, 47, 1-9.	1.8	58
42	Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. American Journal of Kidney Diseases, 2002, 40, 549-555.	1.9	54
43	Effect of Dialysate Sodium Concentration on Interdialytic Increase of Potassium. Journal of the American Society of Nephrology: JASN, 2000, 11, 2337-2343.	6.1	53
44	Prevalence and clinical correlates of white coat hypertension in chronic kidney disease. Nephrology Dialysis Transplantation, 2007, 22, 2217-2223.	0.7	47
45	Independent Role of Underlying Kidney Disease on Renal Prognosis of Patients with Chronic Kidney Disease under Nephrology Care. PLoS ONE, 2015, 10, e0127071.	2.5	47
46	SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects. Medicina (Lithuania), 2019, 55, 268.	2.0	47
47	Sex Differences in the Progression of CKD Among Older Patients: Pooled Analysis of 4 Cohort Studies. American Journal of Kidney Diseases, 2020, 75, 30-38.	1.9	46
48	Hemoglobin Variability in Nondialysis Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1176-1182.	4.5	44
49	Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients. Nephrology Dialysis Transplantation, 2012, 27, 2880-2886.	0.7	43
50	Very low-protein diet plus ketoacids in chronic kidney disease and risk of death during end-stage renal disease: a historical cohort controlled study. Nephrology Dialysis Transplantation, 2015, 30, 71-77.	0.7	43
51	Management of Hypertension in Patients With CKD: Differences Between Primary and Tertiary Care Settings. American Journal of Kidney Diseases, 2005, 46, 18-25.	1.9	42
52	Blood Pressure Variability, Mortality, and Cardiovascular Outcomes in CKD Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 233-240.	4.5	39
53	Burden of Resistant Hypertension in Hypertensive Patients with Non-Dialysis Chronic Kidney Disease. Kidney and Blood Pressure Research, 2011, 34, 58-67.	2.0	38
54	Randomized, double-blind, placebo-controlled study of arginine supplementation in chronic renal failure. Kidney International, 1999, 56, 674-684.	5.2	36

#	Article	IF	CITATIONS
55	Different rates of progression and mortality in patients with chronic kidney disease at outpatient nephrology clinics across Europe. Kidney International, 2018, 93, 1432-1441.	5.2	36
56	Relationship between albuminuric CKD and diabetic retinopathy in a real-world setting of type 2 diabetes: Findings from No blind study. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 923-930.	2.6	33
57	Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis. Kidney International, 2003, 63, 2214-2221.	5.2	32
58	Reclassification of chronic kidney disease patients for end-stage renal disease risk by proteinuria indexed to estimated glomerular filtration rate: multicentre prospective study in nephrology clinics. Nephrology Dialysis Transplantation, 2020, 35, 138-147.	0.7	32
59	Intra- and post-dialytic changes of haemoglobin concentrations in non-anaemic haemodialysis patients. Nephrology Dialysis Transplantation, 2003, 18, 2606-2612.	0.7	30
60	Variations in 24-Hour BP Profiles in Cohorts of Patients with Kidney Disease around the World. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1348-1357.	4.5	30
61	Sodium removal by peritoneal dialysis: a systematic review and meta-analysis. Journal of Nephrology, 2019, 32, 231-239.	2.0	30
62	Daily nutrient intake represents a modifiable determinant of nutritional status in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2003, 18, 1874-1881.	0.7	29
63	Conversion of Darbepoetin to Low Doses of CERA Maintains Hemoglobin Levels in Non-Dialysis Chronic Kidney Disease Patients. Blood Purification, 2010, 30, 186-194.	1.8	28
64	Prevalence and Prognosis of Mild Anemia in Non-Dialysis Chronic Kidney Disease: A Prospective Cohort Study in Outpatient Renal Clinics. American Journal of Nephrology, 2010, 32, 533-540.	3.1	28
65	Safety and effectiveness of low-protein diet supplemented with ketoacids in diabetic patients with chronic kidney disease. BMC Nephrology, 2018, 19, 110.	1.8	28
66	Epidemiology of CKD Regression in Patients under Nephrology Care. PLoS ONE, 2015, 10, e0140138.	2.5	27
67	Short-term blood pressure variability in nondialysis chronic kidney disease patients. Journal of Hypertension, 2018, 36, 2398-2405.	0.5	26
68	Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care. Journal of Clinical Medicine, 2018, 7, 499.	2.4	26
69	Epidemiology of low-proteinuric chronic kidney disease in renal clinics. PLoS ONE, 2017, 12, e0172241.	2.5	26
70	Early detection of progressive renal dysfunction in patients with coronary artery disease. Kidney International, 2005, 68, 2773-2780.	5.2	25
71	Stability of Target Hemoglobin Levels during the First Year of Epoetin Treatment in Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 938-946.	4.5	25
72	Effect of furosemide on left ventricular mass in non-dialysis chronic kidney disease patients: a randomized controlled trial. Nephrology Dialysis Transplantation, 2011, 26, 1575-1583.	0.7	24

#	Article	IF	CITATIONS
73	Resistant Hypertension in Nondialysis Chronic Kidney Disease. International Journal of Hypertension, 2013, 2013, 1-8.	1.3	24
74	Worldwide growing epidemic of CKD: fact or fiction?. Kidney International, 2016, 90, 482-484.	5.2	24
75	No additional benefit of prescribing a very low-protein diet in patients with advanced chronic kidney disease under regular nephrology care: a pragmatic, randomized, controlled trial. American Journal of Clinical Nutrition, 2022, 115, 1404-1417.	4.7	24
76	Nephroprotection by SGLT2 Inhibition: Back to the Future?. Journal of Clinical Medicine, 2020, 9, 2243.	2.4	23
77	CKD in the Elderly: Kidney Senescence or Blood Pressure–Related Nephropathy?. American Journal of Kidney Diseases, 2015, 66, 184-186.	1.9	22
78	Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. Journal of Nephrology, 2016, 29, 71-78.	2.0	22
79	Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study. BMC Nephrology, 2012, 13, 150.	1.8	21
80	Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: Multicenter prospective study in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 756-762.	2.6	21
81	Birth Defects in Gaza: Prevalence, Types, Familiarity and Correlation with Environmental Factors. International Journal of Environmental Research and Public Health, 2012, 9, 1732-1747.	2.6	20
82	Italian Audit on Therapy of Hypertension in Chronic Kidney Disease: The TABLE-CKD Study. Seminars in Nephrology, 2005, 25, 425-430.	1.6	19
83	Controversial issues in CKD clinical practice: position statement of the CKD-treatment working group of the Italian Society of Nephrology. Journal of Nephrology, 2017, 30, 159-170.	2.0	19
84	Epoetin Therapy and Hemoglobin Level Variability in Nondialysis Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 552-559.	4.5	18
85	Stage 5-CKD under nephrology care: to dialyze or not to dialyze, that is the question. Journal of Nephrology, 2016, 29, 153-161.	2.0	18
86	Effects of age on hypertensive status in patients with chronic kidney disease. Journal of Hypertension, 2007, 25, 2325-2333.	0.5	17
87	Dipping Status, Ambulatory Blood Pressure Control, Cardiovascular Disease, and Kidney Disease Progression: A Multicenter Cohort Study of CKD. American Journal of Kidney Diseases, 2023, 81, 15-24.e1.	1.9	17
88	Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects. Diagnostics, 2021, 11, 290.	2.6	16
89	Diuretics in Renal Failure. Mineral and Electrolyte Metabolism, 1999, 25, 32-38.	1.1	15
90	Management of hypertension in chronic kidney disease. Current Hypertension Reports, 2006, 8, 497-501.	3.5	15

#	Article	IF	Citations
91	Responsiveness to Erythropoiesis-Stimulating Agents in Chronic Kidney Disease: Does Geography Matter?. Drugs, 2014, 74, 159-168.	10.9	15
92	Clinical policies on the management of chronic kidney disease patients in Italy. Nephrology Dialysis Transplantation, 2007, 23, 621-626.	0.7	14
93	Intradialytic Changes of Plasma Amino Acid Levels: Effect of Hemodiafiltration with Endogenous Reinfusion versus Acetate-Free Biofiltration. Blood Purification, 2010, 30, 166-171.	1.8	14
94	Assessment of Nutritional Practice in Italian Chronic Kidney Disease Clinics: A Questionnaire-Based Survey., 2010, 20, 82-90.		14
95	Prediabetes as a Precursor to Diabetic Kidney Disease. American Journal of Kidney Diseases, 2016, 67, 817-819.	1.9	13
96	Are all erythropoiesis-stimulating agents created equal?. Nephrology Dialysis Transplantation, 2021, 36, 1369-1377.	0.7	13
97	Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 267-274.	0.7	13
98	ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?. Journal of Clinical Medicine, 2021, 10, 839.	2.4	13
99	Effect of hemodiafiltration with endogenous reinfusion on overt idiopathic chronic inflammation in maintenance hemodialysis patients: A multicenter longitudinal study. Hemodialysis International, 2014, 18, 758-766.	0.9	12
100	Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients. American Journal of Kidney Diseases, 2016, 68, 170-172.	1.9	12
101	Mesangial hypercellularity predicts antiproteinuric response to dual blockade of RAS in primary glomerulonephritis. Kidney International, 2006, 70, 1170-1176.	5.2	11
102	Pro: Thresholds to define chronic kidney disease should not be age-dependent. Nephrology Dialysis Transplantation, 2014, 29, 770-774.	0.7	11
103	Effect of post-nephrectomy acute kidney injury on renal outcome: a retrospective long-term study. World Journal of Urology, 2018, 36, 59-63.	2.2	11
104	Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care. PLoS ONE, 2018, 13, e0202417.	2.5	11
105	Sex difference in ambulatory blood pressure control associates with risk of ESKD and death in CKD patients receiving stable nephrology care. Nephrology Dialysis Transplantation, 2021, 36, 2000-2007.	0.7	11
106	Current Management of Hyperkalemia in Non-Dialysis CKD: Longitudinal Study of Patients Receiving Stable Nephrology Care. Nutrients, 2021, 13, 942.	4.1	11
107	Reassessment of Ambulatory Blood Pressure Improves Renal Risk Stratification in Nondialysis Chronic Kidney Disease. Hypertension, 2015, 66, 557-562.	2.7	10
108	Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease. Expert Opinion on Investigational Drugs, 2021, 30, 253-262.	4.1	10

#	Article	IF	CITATIONS
109	New-onset anemia and associated risk of ESKD and death in non-dialysis CKD patients: a multicohort observational study. CKJ: Clinical Kidney Journal, 2022, 15, 1120-1128.	2.9	10
110	Effect of posture on sodium excretion and diuretic efficacy in nephrotic patients. American Journal of Kidney Diseases, 2000, 36, 719-727.	1.9	9
111	Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8Âyears follow-up of NID-2 study. Acta Diabetologica, 2015, 52, 239-247.	2.5	9
112	Sodium toxicity in peritoneal dialysis: mechanisms and "solutions― Journal of Nephrology, 2020, 33, 59-68.	2.0	9
113	Endothelin-1 released by vascular smooth muscle cells enhances vascular responsiveness of rat mesenteric arterial bed exposed to high perfusion flow. American Journal of Hypertension, 1999, 12, 1119-1123.	2.0	8
114	Supplemented very low-protein diet in advanced CRF: Is it money saving?. Kidney International, 2004, 65, 742.	5.2	8
115	Interaction between phosphorus and parathyroid hormone in non-dialysis CKD patients under nephrology care. Journal of Nephrology, 2014, 27, 57-63.	2.0	8
116	Efficacy of Erythropoietin on Dialysis in Patients with Beta Thalassemia Minor. Blood Purification, 2004, 22, 453-460.	1.8	7
117	Anaemia Management in Non-Dialysis Chronic Kidney Disease: Flexibility of Target to Target Stability?. Nephron Clinical Practice, 2010, 114, c236-c241.	2.3	7
118	Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients. Clinical Drug Investigation, 2017, 37, 965-973.	2.2	7
119	Retarding Chronic Kidney Disease (CKD) Progression: A Practical Nutritional Approach for Non-Dialysis CKD. Nephrology @ Point of Care, 2016, 2, pocj.5000207.	0.2	6
120	Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8Âyears follow up study. Cardiovascular Diabetology, 2016, 15, 147.	6.8	6
121	Area Deprivation and Risk of Death and CKD Progression: Long-Term Cohort Study in Patients under Unrestricted Nephrology Care. Nephron, 2020, 144, 488-497.	1.8	6
122	Prevalence and renal prognosis of left ventricular diastolic dysfunction in non-dialysis chronic kidney disease patients with preserved systolic function. Journal of Hypertension, 2022, 40, 723-731.	0.5	6
123	Effects of Efficiency and Length of Acetate-Free Biofiltration Session on Postdialysis Solute Rebound. American Journal of Kidney Diseases, 2006, 47, 1045-1054.	1.9	5
124	Intestinal adsorption of uraemic toxins: a new strategy for anaemia management?. Nephrology Dialysis Transplantation, 2014, 29, 1620-1624.	0.7	5
125	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of nephrology (SIN), Digestive and Liver Disease, 2018, 50, 1133-1152.	0.9	5
126	Generalizability of SPRINT-CKD cohort to CKD patients referred to renal clinics. Journal of Nephrology, 2019, 32, 429-435.	2.0	5

#	Article	IF	CITATIONS
127	Costâ€analysis of persistent hyperkalaemia in nonâ€dialysis chronic kidney disease patients under nephrology care in Italy. International Journal of Clinical Practice, 2020, 74, e13475.	1.7	5
128	Hypertension management in chronic kidney disease: translating guidelines into daily practice. Journal of Nephrology, 2011, 24, 733-741.	2.0	5
129	Chronic Hyperkaliemia in Chronic Kidney Disease: An Old Concern with New Answers. International Journal of Molecular Sciences, 2022, 23, 6378.	4.1	5
130	Renin–angiotensin system inhibitors reduce the progression of mesangioproliferative glomerulonephritis: 10year follow-up. European Journal of Internal Medicine, 2011, 22, e90-e94.	2.2	4
131	Antiproteinuric Response to Add-on Aliskiren in Proteinuric Patients Treated With Dual Blockade of the Renin-Angiotensin System: A 12-Month Prospective Uncontrolled Study. American Journal of Kidney Diseases, 2011, 57, 961-963.	1.9	4
132	Conversion from Epoetin and Darbepoetin to C.E.R.A. in Non-Dialysis CKD Patients: A Multicenter Italian Prospective Study in Nephrology Practice. Blood Purification, 2013, 36, 69-77.	1.8	4
133	Prevalence of hepatitis C virus infection in non-dialysis CKD patients: a multicentre study in renal clinics. Nephrology Dialysis Transplantation, 2021, 36, 2348-2350.	0.7	4
134	Salt intake correlates with night systolic blood pressure in non-dialytic chronic kidney disease. Nephrology Dialysis Transplantation, 2022, 37, 1387-1389.	0.7	4
135	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of nephrology (SIN), Journal of Nephrology, 2018, 31, 685-712.	2.0	3
136	Central Venous Stenosis after Hemodialysis: Case Reports and Relationships to Catheters and Cardiac Implantable Devices. CardioRenal Medicine, 2019, 9, 135-144.	1.9	3
137	Anemia: A Connection Between Heart Failure and Kidney Failure. Cardiology Clinics, 2021, 39, 319-333.	2.2	3
138	Risk of end-stage kidney disease in kidney transplant recipients versus patients with native chronic kidney disease: multicentre unmatched and propensity-score matched analyses. Nephrology Dialysis Transplantation, 2023, 38, 507-516.	0.7	3
139	Is the Type of Hemodialysis Important to Control Serum Phosphate?. Blood Purification, 2006, 24, 299-300.	1.8	2
140	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of nephrology (SIN). Internal and Emergency Medicine, 2018, 13, 1139-1166.	2.0	2
141	Ferric Carboxymatose in Non-Hemodialysis CKD Patients: A Longitudinal Cohort Study. Journal of Clinical Medicine, 2021, 10, 1322.	2.4	2
142	Major structural birth defects in children aged 0–2 years in the Gaza Strip: a cross-sectional study. Lancet, The, 2012, 380, S32.	13.7	1
143	15-year-change of phenotype and prognosis in non-dialysis CKD patients referred to a nephrology clinic. International Urology and Nephrology, 2022, 54, 679-686.	1.4	1
144	Volume-Independent Sodium Toxicity in Peritoneal Dialysis: New Insights from Bench to Bed. International Journal of Molecular Sciences, 2021, 22, 12804.	4.1	1

#	Article	IF	CITATIONS
145	Nephroprotection with saxagliptin. Giornale Italiano Di Nefrologia: Organo Ufficiale Della Società Italiana Di Nefrologia, 2015, 32, .	0.3	1
146	Maximal suppression of renin-angiotensin system in patients with refractory proteinuria. American Journal of Hypertension, 2003, 16, A1.	2.0	0
147	The Importance of Ambulatory and Home Monitoring Blood Pressure in Resistant Hypertension Associated with Chronic Kidney Disease., 2017,, 39-58.		O
148	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of nephrology (SIN), Infection, 2019, 47, 141-168.	4.7	0
149	MO464TWO-YEARS CHANGES IN ABPM, CARDIAC AND RENAL PARAMETERS PREDICT CARDIOVASCULAR OUTCOME OF PATIENTS WITH CKD AND HYPERTENSION. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
150	A new CHA2DS2VASC score integrated with estimated glomerular filtration rate, left ventricular hypertrophy, and pulse pressure is highly effective in predicting adverse cardiovascular outcome in chronic kidney disease. European Journal of Preventive Cardiology, 2022, , .	1.8	0
151	Changes over time in ambulatory blood pressure and cardiac parameters predict cardiovascular outcome of patients with CKD and low cardiovascular morbidity. Journal of Nephrology, 0, , .	2.0	O